2019
Surgery Versus Surveillance for Well‐Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11‐Year Analysis of the National Cancer Database
Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well‐Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11‐Year Analysis of the National Cancer Database. The Oncologist 2019, 25: e276-e283. PMID: 32043766, PMCID: PMC7011621, DOI: 10.1634/theoncologist.2019-0466.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseIndependent prognostic factorPancreatic neuroendocrine tumorsCharlson-Deyo comorbidity scoreNonfunctional pancreatic neuroendocrine tumorsImproved overall survivalSurgical resectionNF-PanNETOverall survivalPrognostic factorsTumor sizeNeuroendocrine tumorsActive surveillanceCancer DatabaseComorbidity scoreClinicopathologic characteristicsLarge tumorsTumor locationProspective randomized clinical trialsSafe approachActive interventionLarge asymptomatic tumorTumor size 1Underwent surgical resectionPatients' clinicopathologic characteristics
2014
Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.
Pollom E, Alagappan M, Chan C, Shultz D, Kunz P, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 317-317. DOI: 10.1200/jco.2014.32.3_suppl.317.Peer-Reviewed Original ResearchStereotactic body radiotherapyUnresectable pancreatic adenocarcinomaGy x 5Pancreatic adenocarcinomaPrior RTCurrent chemoResectable diseaseTumor locationTime of SBRTToxicity of SBRTLocal controlBorderline resectable diseaseGood local controlUse of chemotherapyDate of diagnosisCommon treatment regimensBetter OSMedian OSOS ratesAdvanced diseaseGI toxicityCumulative incidenceLocal recurrenceBody radiotherapyTreatment regimens